Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Study Identifies New Therapeutic Target for Tumor Treatment
Disease Discoveries

Study Identifies New Therapeutic Target for Tumor Treatment

By Olivia DimmerDec 16, 2022
Share
Facebook Twitter Email
Deyu Fang, PhD, the Hosmer Allen Johnson Professor of Pathology and a member of the Robert H. Lurie Comprehensive Cancer Center was senior author of the study published in Science Advances.

Northwestern Medicine scientists have identified a new therapeutic target for tumors and developed a compound which slowed tumor growth and bolsters immune responses in mice, according to research published in Science Advances.

The study authors first characterized the regulatory T-cells (Treg) — which act to prevent autoimmune responses — inside different types of cancerous tumors in human cancer samples and mouse models. While normal Treg cells work to temper autoimmune reactions like inflammation, these cells begin to behave differently once inside a tumor, effectively working to block the body’s anti-cancer efforts.

This phenomenon, called Treg fitness, has not been well understood until now, said Deyu Fang, PhD, the Hosmer Allen Johnson Professor of Pathology and senior author of the study.

“Tumor cells are smart. They take the immuno-suppressive Treg and use it to suppress anti-tumor responses,” said Fang, a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “Even more so, the tumor makes these immuno-suppressive cells inside the tumor microenvironment even more suppressive than cells would be in normal populations, for example in the lymph nodes. So, the first question is: ‘Why does Treg become more suppressive?’ This paper provides the first answer.”

Investigators found that Treg cells inside tumors had higher levels of the protein FOXP3, which is known as a master regulator of the pathways involved in Treg development and function.

To understand why these cells produced more FOXP3, scientists increased levels of transforming
growth factor–beta, a substance thought to play a role in Treg stability. According to the study, this resulted in increased levels of USP21 and USP22, proteins that protect FOXP3 from ubiquitin-mediated degradation in the cell.

Because targeting FOXP3 could result in an autoimmune response, scientists deleted USP21 and USP22 inside Treg cells in mice and found tumor growth slowed as a result.

“This study defines the first molecular pathway controlling Treg fitness,” Fang said. “We’ve also identified USP22 as an ideal therapeutic target.”

Investigators then sought to identify an inhibitor for USP22, which appeared to have the largest effect on tumor proliferation. Utilizing computer-aided drug design, the study authors identified a compound that slowed tumor growth and increased tumor rejection in mouse models without killing healthy cells.

With the compound now patented by Exomira Medicine, a start-up he co-founded with Huiping Liu, MD, PhD, associate professor of Pharmacology and Medicine in the division of Hematology and Oncology, Fang said he hopes to move to clinical trials in the future.

“Since our lab has discovered that USP22 also functions as an oncogene in cancer cells, this compound acts as chemotherapy and immunotherapy. It does both, which is why it can achieve this level of efficacy we see in slowing tumor growth,” Fang said. “We’re looking to move forward with the small molecule inhibitor we have identified, which is potentially translatable for cancer therapy.”

This study was supported by National Institutes of Health R01 grants AI079056, AI108634, and CA232347 and NIH National Cancer Institute (NCI) F31 CA220801.

Cancer Immunology Pathology Research
Share. Facebook Twitter Email

Related Posts

Longtime Alcohol Consumption Speeds Up Biological Aging 

Feb 3, 2023

Grant Provides Imaging Technology to Department of Ophthalmology

Feb 2, 2023

Gender-Affirming Hormones Improve Mental Health in Transgender and Nonbinary Youth

Feb 2, 2023

Comments are closed.

Latest News

Longtime Alcohol Consumption Speeds Up Biological Aging 

Feb 3, 2023

Grant Provides Imaging Technology to Department of Ophthalmology

Feb 2, 2023

Gender-Affirming Hormones Improve Mental Health in Transgender and Nonbinary Youth

Feb 2, 2023

Investigating the Connection Between Steps and Heart Disease Risk

Feb 1, 2023

Medical School Faculty Named AAAS Fellows

Jan 31, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
Feinberg_In_Vivo_20221209_tcrawford-24
Feinberg_In_Vivo_20221209_tcrawford-16
Feinberg_In_Vivo_20221209_tcrawford-14
Feinberg_In_Vivo_20221209_tcrawford-5
Feinberg_In_Vivo_20221209_tcrawford-6
Feinberg_In_Vivo_20221209_tcrawford-10
Feinberg_In_Vivo_20221209_tcrawford-8
Feinberg_In_Vivo_20221209_tcrawford-18
Feinberg_In_Vivo_20221209_tcrawford
Feinberg_In_Vivo_20221209_tcrawford-23
Feinberg_In_Vivo_20221209_tcrawford-25
Feinberg_In_Vivo_20221209_tcrawford-26

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.